Biology of advanced uveal melanoma and next steps for clinical therapeutics
Year: 2014
Type: article
Abstract: Uveal melanoma is the most common intraocular malignancy although it is a rare subset of all melanomas. Uveal melanoma has distinct biology relative to cutaneous melanoma, with widely divergent patient outcomes. Patients diagnosed with a primary uveal melanoma can be stratified for risk of metastasis by cytogenetics or gene expression profiling, with approximately half of patients developing metastatic disease, predominately hepatic in location, over a 15-yr period. Historically, no systemic therapy has been associated with a clear clinical benefit for patients with advanced disease, and median survival remains poor. Here, as a joint effort between the Melanoma Research Foundation's ocular melanoma initiative, CURE OM and the National Cancer Institute, the current understanding of the molecular and immunobiology of uveal melanoma is reviewed, and on-going laboratory research into the disease is highlighted. Finally, recent investigations relevant to clinical management via targeted and immunotherapies are reviewed, and next steps in the development of clinical therapeutics are discussed.
Source: Pigment Cell & Melanoma Research
DOI: 10.1111/pcmr.12304
Authors: Jason J. Luke, Pierre L. Triozzi, Kyle C. McKenna, Erwin G. Van Meir, Jeffrey E. Gershenwald, Boris C. Bastian, J. Silvio Gutkind, Anne M. Bowcock, Howard Z. Streicher, Poulam M. Patel, Takami Sato, Jeffery A. Sossman, Mario Sznol, Jack Welch, Magdalena Thurin, Sara Selig, Keith T. Flaherty, Richard D. Carvajal
Institutions: Harvard University, Dana-Farber Cancer Institute, Wake Forest University Health Sciences, Wake Forest University, UPMC Hillman Cancer Center, Winship Cancer Institute, The University of Texas MD Anderson Cancer Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, National Institute of Dental and Craniofacial Research, Imperial College London, National Institutes of Health, National Cancer Institute, University of Nottingham, Thomas Jefferson University, Sidney Kimmel Cancer Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Yale Cancer Center, Yale University, Melanoma Research Foundation, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2018172717